ChoA Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
ChoA Pharmaceutical's earnings have been declining at an average annual rate of -31.1%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 0.8% per year.
Key information
-31.1%
Earnings growth rate
-28.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | -0.8% |
| Return on equity | -38.0% |
| Net Margin | -21.1% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How ChoA Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 61,032 | -12,889 | 28,629 | 1,988 |
| 31 Mar 24 | 62,264 | -12,212 | 28,760 | 2,139 |
| 31 Dec 23 | 62,974 | -10,514 | 28,598 | 2,182 |
| 30 Sep 23 | 66,586 | -690 | 23,340 | 2,244 |
| 30 Jun 23 | 68,213 | 1,960 | 21,989 | 2,244 |
| 31 Mar 23 | 69,103 | 1,900 | 22,996 | 1,758 |
| 31 Dec 22 | 68,880 | 561 | 23,710 | 1,302 |
| 30 Sep 22 | 64,523 | -5,203 | 24,927 | 1,422 |
| 30 Jun 22 | 62,833 | -7,061 | 24,855 | 1,422 |
| 31 Mar 22 | 59,475 | -8,042 | 24,399 | 1,422 |
| 31 Dec 21 | 57,561 | -8,044 | 24,055 | 1,422 |
| 30 Sep 21 | 57,331 | -6,084 | 23,631 | 1,542 |
| 30 Jun 21 | 58,238 | -4,142 | 23,760 | 1,542 |
| 31 Mar 21 | 61,611 | -1,649 | 24,568 | 1,542 |
| 31 Dec 20 | 65,360 | -1,319 | 25,361 | 1,542 |
| 30 Sep 20 | 68,683 | -669 | 25,633 | 1,685 |
| 30 Jun 20 | 69,689 | -1,556 | 26,330 | 1,685 |
| 31 Mar 20 | 69,193 | -2,090 | 26,459 | 1,685 |
| 31 Dec 19 | 67,537 | -905 | 26,240 | 1,685 |
| 30 Sep 19 | 65,967 | -2,063 | 26,920 | 1,568 |
| 30 Jun 19 | 64,459 | -685 | 26,344 | 1,568 |
| 31 Mar 19 | 63,804 | 608 | 25,230 | 1,568 |
| 31 Dec 18 | 63,090 | 641 | 25,182 | 1,568 |
| 30 Sep 18 | 62,010 | 3,412 | 24,696 | 1,664 |
| 30 Jun 18 | 62,264 | 3,131 | 24,723 | 1,664 |
| 31 Mar 18 | 60,781 | 2,365 | 25,074 | 1,664 |
| 31 Dec 17 | 58,865 | 1,624 | 25,331 | 1,664 |
| 30 Sep 17 | 58,394 | 590 | 25,414 | 1,720 |
| 30 Jun 17 | 56,679 | 323 | 24,932 | 1,720 |
| 31 Mar 17 | 55,867 | -342 | 24,911 | 1,720 |
| 31 Dec 16 | 55,551 | 163 | 24,020 | 1,720 |
| 30 Sep 16 | 53,940 | 730 | 23,362 | 1,655 |
| 30 Jun 16 | 53,093 | 936 | 22,690 | 1,655 |
| 31 Mar 16 | 51,781 | 1,030 | 22,138 | 1,655 |
| 31 Dec 15 | 50,120 | 1,012 | 21,900 | 1,655 |
| 30 Sep 15 | 48,007 | -1,448 | 22,662 | 2,053 |
| 30 Jun 15 | 46,573 | -2,289 | 22,911 | 2,053 |
| 31 Mar 15 | 44,809 | -3,449 | 22,774 | 2,053 |
| 31 Dec 14 | 43,087 | -4,075 | 22,000 | 2,053 |
| 30 Sep 14 | 43,874 | -758 | 21,272 | 1,290 |
| 30 Jun 14 | 43,798 | 420 | 20,499 | 1,290 |
| 31 Mar 14 | 43,457 | 932 | 20,266 | 1,290 |
| 31 Dec 13 | 43,913 | 1,804 | 20,270 | 1,290 |
| 30 Sep 13 | 42,813 | 793 | 22,388 | 305 |
Quality Earnings: A034940 is currently unprofitable.
Growing Profit Margin: A034940 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A034940 is unprofitable, and losses have increased over the past 5 years at a rate of 31.1% per year.
Accelerating Growth: Unable to compare A034940's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A034940 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.6%).
Return on Equity
High ROE: A034940 has a negative Return on Equity (-38.01%), as it is currently unprofitable.